|Bid||20.02 x 2900|
|Ask||25.00 x 4000|
|Day's Range||21.21 - 22.17|
|52 Week Range||11.65 - 36.65|
|Beta (3Y Monthly)||2.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.67|
How Generic Pharmaceutical Stocks Are Positioned this Month(Continued from Prior Part)Analysts’ recommendations and target prices Wall Street analysts expect upside potential of 35.45% for Mallinckrodt (MNK), based on the company’s closing price
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
STAINES-UPON-THAMES, United Kingdom, March 18, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced that, following an extensive search, Bryan Reasons has been appointed Chief Financial Officer (CFO), effective immediately. Mr. Reasons will join Mallinckrodt's Executive Committee, the company's senior leadership group, and report directly to President and Chief Executive Officer, Mark Trudeau. George Kegler, who has served as interim CFO of Mallinckrodt, will stay on for a transitional period to ensure a smooth transfer of responsibilities prior to retiring from the company. Mr. Reasons brings broad financial leadership experience to Mallinckrodt, which he gained in publicly traded pharmaceutical companies known for their success in research, development and commercialization of branded drugs.
ST. LOUIS, March 15, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (MNK), a leading specialty pharmaceutical company, announced today that sites owned and operated by subsidiaries in its Specialty Generics business have been recognized as Manufacturing Leadership Award winners for outstanding achievement. The awards, granted by the National Association of Manufacturers, were received in two categories – Talent Management Leadership as well as Engineering and Production Technology Leadership.
The opioid crisis came to the loan market last week, as the potential fallout from lawsuits weighed on manufacturers of the drugs cited as a root cause of the epidemic. Pharmaceutical company Endo International’s US$3.4bn term loan was quoted at 97.75-98.5 on Monday, unchanged from Friday but down from 99.625-100.125 on March 4, as its stock fell 23% during the same five-day period. The drop followed a Reuters report that fellow drug producer Purdue Pharma, the maker of OxyContin, was exploring bankruptcy to address liabilities stemming from lawsuits tied to the opioid crisis.
Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Financial performanceIn fiscal 2018, Mallinckrodt’s (MNK) revenue fell 0.19% YoY (year-over-year) to $3.22 billion. Its adjusted diluted EPS rose 6.94% YoY to
Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Gross margin comparison In its fourth-quarter conference call, Endo International (ENDP) guided for its gross margin contracting YoY (year-over-year) in fiscal 2019
Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for its fiscal 2019 adjusted operating expenses as a
Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Earnings guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for adjusted diluted EPS and adjusted EBITDA of
Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Revenue guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for fiscal 2019 revenue of $2.76 billion–$2.96
Comparing Generic Pharma Stocks: Endo versus MallinckrodtStock movement On March 5, Endo International (ENDP) closed at $8.72, 6.54% lower than its previous closing price, 65.46% higher than its 52-week low of $5.27, and 52.86% below its 52-week high
OxyContin is the brand name of oxycodone hydrochloride, which belongs to a class of drug called opioid analgesics. It is a Schedule II controlled substance with abuse potential similar to other Schedule II opioids and is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid when other pain treatments do not work.
STAINES-UPON-THAMES, United Kingdom, March 4, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced data from a retrospective cohort analysis that assessed the potential resource and cost impact of continuation of systemic treatment (ST) on healthcare utilization among U.S. patients with cutaneous T-cell lymphoma (CTCL). The analysis included 1,081 patients with CTCL with continuous enrollment three months before and six months after initiation of ST.
Chevy Chase venture capital juggernaut New Enterprise Associates Inc. is raising a new fund with a ceiling of $3.6 billion, according to a Securities and Exchange Commission filing made Friday. New Enterprise Associates 16, which the company raised in 2017, was $3.5 billion, according to PitchBook. NEA has increased its fund size each time since its first $16 million fund in 1978.